CA · Latest: CA Notice complete
Tempus AI, Inc. will acquire Ambry Genetics Corporation. Both parties previously partnered to distribute germline sequencing for inherited cancer risk and this acquisition intends to further expand inherited risk screening for cancer patients.
| State | Agency | Status | Stage | Source |
|---|---|---|---|---|
| CA | Office of Health Care Affordability (HCAI) | CMIR Waived WAIVED | NOTICE | Agency record |
No changes observed since the initial load (CA ).
| State | Parties as filed |
|---|---|
| CA | Ambry Genetics Corporation; Tempus AI, Inc. |
One agency record. It is not grouped with any other.
| State | Title as printed | Source key | Key method |
|---|---|---|---|
| CA | Ambry Genetics Corporation / and / Tempus AI, Inc. | material-change-transaction-notice-ambry | FIRST_DOCUMENT_SLUG |
| State | Source key | First seen by DocketTrail (UTC) | Last checked (UTC) | Page checked |
|---|---|---|---|---|
| CA | material-change-transaction-notice-ambry | hcai.ca.gov |
| Source | Last captured (UTC) |
|---|---|
| https://hcai.ca.gov/affordability/ohca/assess-market-consolidation/material-change-transaction-notices-mcn-and-cost-and-market-impact-review-cmir/ | 2026-10-06T20:33:54.638Z |